<DOC>
	<DOCNO>NCT00717821</DOCNO>
	<brief_summary>This 2 arm study compare hemoglobin maintenance monthly Mircera administration versus epoetin beta darbepoetin alfa patient chronic kidney disease hemodialysis . Patients randomize receive either monthly s.c. i.v . Mircera ( start dose 120 200 microgram , calculate last weekly dose epoetin beta darbepoetin alfa previously administer ) , standard therapy ( iv sc epoetin beta , twice thrice weekly , iv sc darbepoetin alfa week twice week ) . The anticipated time study treatment 3-12 month , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Once Monthly Intravenous Subcutaneous Mircera Patients With Chronic Kidney Disease Hemodialysis .</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; regular long term hemodialysis schedule &gt; =12 week ; continuous iv sc maintenance epoetin beta darbepoetin alfa therapy , dose interval previous month , change total weekly dose . transfusion red blood cell previous 2 month ; significant acute chronic bleeding ; poorly control hypertension require hospitalization interruption epoetin beta/darbepoetin alfa treatment previous 6 month ; weekly dose epoetin beta &gt; 16000 UI , weekly dose darbepoetin alfa &gt; 80 microgram previous month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>